S
Stefan H. Hohnloser
Researcher at University of Freiburg
Publications - 163
Citations - 20397
Stefan H. Hohnloser is an academic researcher from University of Freiburg. The author has contributed to research in topics: Atrial fibrillation & Myocardial infarction. The author has an hindex of 50, co-authored 163 publications receiving 19231 citations. Previous affiliations of Stefan H. Hohnloser include Technical University of Dortmund & Durham University.
Papers
More filters
Journal ArticleDOI
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof,Stefano Benussi,Dipak Kotecha,Anders Ahlsson,Dan Atar,Barbara Casadei,Manuel Castellá,Hans-Christoph Diener,Hein Heidbuchel,Jeroen M.L. Hendriks,Gerhard Hindricks,Antonis S. Manolis,Jonas Oldgren,Bogdan A. Popescu,Ulrich Schotten,Bart P. Van Putte,Panagiotis Vardas,Stefan Agewall,John Camm,Gonzalo Barón Esquivias,Werner Budts,Scipione Carerj,Filip Casselman,Antonio Coca,Raffaele De Caterina,Spiridon Deftereos,Dobromir Dobrev,José M. Ferro,Gerasimos Filippatos,Donna Fitzsimons,Bulent Gorenek,Maxine Guenoun,Stefan H. Hohnloser,Philippe Kolh,Gregory Y.H. Lip,Athanasios J. Manolis,John J.V. McMurray,Piotr Ponikowski,Raphael Rosenhek,Frank Ruschitzka,Irina Savelieva,Sanjay Sharma,Piotr Suwalski,Juan Tamargo,Clare J Taylor,Isabelle C. Van Gelder,Adriaan A. Voors,Stephan Windecker,José Luis Zamorano,Katja Zeppenfeld +49 more
TL;DR: The Task Force for the management of atrial fibrillation of the European Society of Cardiology has been endorsed by the European Stroke Organisation (ESO).
Journal ArticleDOI
Apixaban in Patients with Atrial Fibrillation
Stuart J. Connolly,John W. Eikelboom,Campbell D. Joyner,Hans-Christoph Diener,Robert G. Hart,Sergey P. Golitsyn,Greg C. Flaker,Alvaro Avezum,Stefan H. Hohnloser,Rafael Diaz,Mario Talajic,Jun Zhu,Prem Pais,Andrzej Budaj,Alexander Parkhomenko,Petr Jansky,Patrick J. Commerford,Ru San Tan,Kui-Hian Sim,Basil S. Lewis,Walter Van Mieghem,Jae Hyung Kim,Fernando Lanas-Zanetti,Antonio Gonzalez-Hermosillo,Antonio L. Dans,Muhammad Munawar,John H. Lawrence,Gayle Lewis,Rizwan Afzal,Salim Yusuf +29 more
TL;DR: In patients with atrial fibrillation for whom vitamin K antagonist therapy was unsuitable, apixaban reduced the risk of stroke or systemic embolism without significantly increasing therisk of major bleeding or intracranial hemorrhage.
Journal ArticleDOI
2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation
A. John Camm,Gregory Y.H. Lip,Raffaele De Caterina,Irene Savelieva,Dan Atar,Stefan H. Hohnloser,Gerhard Hindricks,Paulus Kirchhof +7 more
Journal ArticleDOI
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Christopher P. Cannon,Deepak L. Bhatt,Jonas Oldgren,Gregory Y.H. Lip,Stephen G. Ellis,Takeshi Kimura,Michael Maeng,Béla Merkely,Uwe Zeymer,Savion Gropper,Matias Nordaby,Eva Kleine,Ruth Harper,Jenny Manassie,James L. Januzzi,Jurriën M. ten Berg,P. Gabriel Steg,Stefan H. Hohnloser +17 more
TL;DR: Among patients with atrial fibrillation who had undergone PCI, the risk of bleeding was lower among those who received dual therapy with dabigatran and a P2Y12 inhibitor than amongThose who received triple therapy with warfarin, a P1Y12 inhibitors, and aspirin.
Journal Article
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
Stefan H. Hohnloser,Harry J.G.M. Crijns,Martin van Eickels,Christophe Gaudin,Richard L. Page,Christian Torp-Pedersen,Stuart J. Connolly +6 more
TL;DR: Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation and had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash and an increased serum creatinine level than the placebo group.